USANA Stock Plummets on Weak Q2 Results and Revenue Slump in Growth Brands

Key Facts

Amid mounting pressure on the direct-selling business model, USANA Health Sciences faced a sharp sell-off following the release of Q2 results that missed expectations. According to reports, the company's stock fell significantly as its core business continued to contract, sparking investor concerns regarding near-term growth sustainability.

Financial data revealed concerning performance for the company's growth-focused brands, with both Hiya and Rise Wellness reporting plummeting revenues. This operational deterioration compounds the impact of the previously announced $29 million impairment charge for Hiya, leading to analyst downgrades due to a lack of clear growth catalysts in the current environment.

Traders should monitor technical support levels following the recent price drop, as market focus shifts to management's ability to stabilize revenue across its new brand portfolio. According to the economic calendar, there are no major sector-specific events scheduled for the next seven days, leaving price action driven by ongoing market reaction to the earnings miss and the revised 2026 outlook.